PPISURV: A novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome

Oncogene

Volumn 33, Issue 13, 2014, Pages 1621-1628

  Antonov, A V ^a,b   Krestyaninova, M ^c   Knight, R A ^a   Rodchenkov, I ^d   Melino, G ^a,b,e   Barlev, N A ^a,b,f  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b State Technological University   (Russian Federation)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF TORONTO   (Canada)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f INSTITUTE OF CYTOLOGY   (Russian Federation)

Author keywords

Bioinformatics; Computational oncology; Survival

Indexed keywords

PROTEIN BCL 2; PROTEIN P21; PROTEIN P53;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER SURVIVAL; DATA MINING; GENE; GENE BCL 2; GENE EXPRESSION; GENE INTERACTION; GENE P21; GENE P53; GENE TP73; GENETIC DATABASE; GLIOBLASTOMA; HUMAN; LARGE CELL LYMPHOMA; LIPOSARCOMA; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT NEOPLASTIC DISEASE; MENINGIOMA; MULTIPLE MYELOMA; NUCLEOTIDE SEQUENCE; ONLINE SYSTEM; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TP73 GENE;

COMPUTATIONAL BIOLOGY; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; GENES, P53; HUMANS; NEOPLASMS; NUCLEAR PROTEINS; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEINS;

EID: 84898015237     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.119     Document Type: Article

References (29)

1. Barrett T, Troup DB, Wilhite SE, Ledoux P, Rudnev D, Evangelista C, et al. NCBI GEO: Archive for high-Throughput functional genomic data. Nucleic Acids Res 2009; 37: D885-D890
2. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, et al. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 2005; 102: 13550-13555
3. Gyorffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q, et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat 2010; 123: 725-731
4. Gyorffy B, Lanczky A, Szallasi Z. Implementing an online tool for genome-wide validation of survival-Associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 2012; 19: 197-208
5. Antonov AV, Knight RA, Melino G, Barlev NA, Tsvetkov PO. MIRUMIR: An online tool to test microRNAs as biomarkers to predict survival in cancer using multiple clinical data sets. Cell Death Differ 2013; 20: 367
6. Na II, Rho JK, Choi YJ, Kim CH, Koh JS, Ryoo BY, et al. Clinical features reflect exon sites of EGFR mutations in patients with resected non-small-cell lung cancer. J Korean Med Sci 2007; 22: 393-399
7. Tandon S, Tudur-Smith C, Riley RD, Boyd MT, Jones TM. A systematic review of p53 as a prognostic factor of survival in squamous cell carcinoma of the four main anatomical subsites of the head and neck. Cancer Epidemiol Biomarkers Prev 2010; 19: 574-587.
8. Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res 2004; 10: 3815-3824
9. Kerrien S, Aranda B, Breuza L, Bridge A, Broackes-Carter F, Chen C, et al. The IntAct molecular interaction database in 2012. Nucleic Acids Res 2012; 40: D841-D846
10. Croft D, O'Kelly G, Wu G, Haw R, Gillespie M, Matthews L, et al. Reactome: A database of reactions, pathways and biological processes. Nucleic Acids Res 2011; 39: D691-D697
11. Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: A comprehensive resource for investigating the structure and function of experimentally determined post-Translational modifications in man and mouse. Nucleic Acids Res 2012; 40: D261-D270
12. Dietmann S, Lee W, Wong P, Rodchenkov I, Antonov AV. CCancer: A bird's eye view on gene lists reported in cancer-related studies. Nucleic Acids Res 2010; 38: W118-W123
13. Antonov AV, Schmidt EE, Dietmann S, Krestyaninova M, Hermjakob H. R Spider: A network-based analysis of gene lists by combining signaling and metabolic pathways from reactome and KEGG databases. Nucleic Acids Res 2010; 38: W78-W83
14. Antonov AV. BioProfiling.de: Analytical web portal for high-Throughput cell biology. Nucleic Acids Res 2011; 39: W323-W327
15. Lee JT, Gu W. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ 2010; 17: 86-92
16. Tomasini R, Mak TW, Melino G. The impact of p53 and p73 on aneuploidy and cancer. Trends Cell Biol 2008; 18: 244-252
17. Rufini A, Agostini M, Grespi F, Tomasini R, Sayan BS, Niklison-Chirou MV, et al. p73 in Cancer. Genes Cancer 2011; 2: 491-502
18. Levine AJ, Tomasini R, McKeon FD, Mak TW, Melino G. The p53 family: Guardians of maternal reproduction. Nat Rev Mol Cell Biol 2011; 12: 259-265
19. Suzuki A, Tsutomi Y, Akahane K, Araki T, Miura M. Resistance to Fas-mediated apoptosis: Activation of caspase 3 is regulated by cell cycle regulator p21WAF1 and IAP gene family ILP. Oncogene 1998; 17: 931-939
20. Gartel AL, Radhakrishnan SK. Lost in transcription: P21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985
21. Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res 2006; 12: 2468-2475
22. Castiglione F, Sarotto I, Fontana V, Destefanis M, Venturino A, Ferro S, et al. Bcl2, p53 and clinical outcome in a series of 138 operable breast cancer patients. Anticancer Res 1999; 19: 4555-4563
23. Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le QJ, et al. BCL2 in breast cancer: A favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer 2010; 103: 668-675
24. Ciardiello F, Tortora G. Inhibition of bcl-2 as cancer therapy. Ann Oncol 2002; 13: 501-502
25. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, et al. The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004; 32: D258-D261
26. Wu H, Zeinab RA, Flores ER, Leng RP. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination. Mol Cancer Res 2011; 9: 1780-1790
27. Malatesta M, Peschiaroli A, Memmi EM, Zhang J, Antonov A, Green DR, et al. The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity. Oncogene 2013; 32: 4721-4726
28. Hochberg Y, Benjamini Y. More powerful procedures for multiple significance testing. Stat Med 1990; 9: 811-818
29. Harrington F. A class of rank test procedures for censored survival data. Biometrika 1982; 69: 553-566.